| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tamsulosin HCl, a marketed drug, is a potent and selective α1a adrenergic receptor antagonist used for the treatment of benign prostatic hyperplasia (BPH). It exhibits a preference for the α1A receptor found in the prostate as opposed to the α1B receptor found in blood vessels. Compared to control patients, tamsulosin-treated patients had a 0.30-fold decreased risk of experiencing acute urinary retention. Tamsulosin can be suggested as a treatment for men who have had AUR catheterization, as it can lessen the chance that they will require another catheterization.
| Targets |
α1-adrenergic receptor
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Tamsulosin hydrochloride is a hydrochloride resulting from the reaction of equimolar amounts of tamulosin and hydrogen chloride. It has a role as an alpha-adrenergic antagonist and an antineoplastic agent. It contains a tamsulosin(1+). It is an enantiomer of an ent-tamsulosin hydrochloride.
Tamsulosin Hydrochloride is the hydrochloride salt of tamsulosin, a sulfonamide derivative with adrenergic antagonist activity. Tamsulosin selectivity binds to and blocks the activity of alpha1 adrenoreceptors in the human prostate and bladder neck; blockade of these adrenoceptors can cause smooth muscle in the prostate and bladder neck to relax, resulting in an improvement in urinary flow rate. A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA. See also: Tamsulosin (annotation moved to). |
| Molecular Formula |
C20H28N2O5S.HCL
|
|
|---|---|---|
| Molecular Weight |
444.97
|
|
| Exact Mass |
444.148
|
|
| Elemental Analysis |
C, 55.00; H, 6.56; Cl, 8.54; N, 6.75; O, 15.42; S, 7.73
|
|
| CAS # |
106463-17-6
|
|
| Related CAS # |
Tamsulosin;106133-20-4; Tamsulosin-d5 hydrochloride; Tamsulosin-d4 hydrochloride; 2518100-55-3
|
|
| PubChem CID |
5362376
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
595.5ºC at 760 mmHg
|
|
| Melting Point |
228-230ºC
|
|
| Flash Point |
313.9ºC
|
|
| Vapour Pressure |
3.79E-14mmHg at 25°C
|
|
| LogP |
4.512
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
11
|
|
| Heavy Atom Count |
29
|
|
| Complexity |
539
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
Cl[H].S(C1=C(C([H])=C([H])C(=C1[H])C([H])([H])[C@@]([H])(C([H])([H])[H])N([H])C([H])([H])C([H])([H])OC1=C([H])C([H])=C([H])C([H])=C1OC([H])([H])C([H])([H])[H])OC([H])([H])[H])(N([H])[H])(=O)=O
|
|
| InChi Key |
ZZIZZTHXZRDOFM-XFULWGLBSA-N
|
|
| InChi Code |
InChI=1S/C20H28N2O5S.ClH/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24;/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24);1H/t15-;/m1./s1
|
|
| Chemical Name |
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2473 mL | 11.2367 mL | 22.4734 mL | |
| 5 mM | 0.4495 mL | 2.2473 mL | 4.4947 mL | |
| 10 mM | 0.2247 mL | 1.1237 mL | 2.2473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH
CTID: NCT04987892
Phase: Phase 4 Status: Recruiting
Date: 2023-04-25
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
